Innoviva Total Current Assets 2010-2024 | INVA
Innoviva total current assets from 2010 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
Innoviva Annual Total Current Assets
(Millions of US $) |
| 2023 |
$344 |
| 2022 |
$444 |
| 2021 |
$314 |
| 2020 |
$342 |
| 2019 |
$431 |
| 2018 |
$199 |
| 2017 |
$200 |
| 2016 |
$198 |
| 2015 |
$214 |
| 2014 |
$252 |
| 2013 |
$483 |
| 2012 |
$261 |
| 2011 |
$245 |
| 2010 |
$316 |
| 2009 |
$162 |
Innoviva Quarterly Total Current Assets
(Millions of US $) |
| 2024-06-30 |
$358 |
| 2024-03-31 |
$311 |
| 2023-12-31 |
$344 |
| 2023-09-30 |
$305 |
| 2023-06-30 |
$324 |
| 2023-03-31 |
$296 |
| 2022-12-31 |
$444 |
| 2022-09-30 |
$455 |
| 2022-06-30 |
$400 |
| 2022-03-31 |
$318 |
| 2021-12-31 |
$314 |
| 2021-09-30 |
$237 |
| 2021-06-30 |
$148 |
| 2021-03-31 |
$373 |
| 2020-12-31 |
$342 |
| 2020-09-30 |
$572 |
| 2020-06-30 |
$500 |
| 2020-03-31 |
$467 |
| 2019-12-31 |
$431 |
| 2019-09-30 |
$367 |
| 2019-06-30 |
$318 |
| 2019-03-31 |
$252 |
| 2018-12-31 |
$199 |
| 2018-09-30 |
$121 |
| 2018-06-30 |
$179 |
| 2018-03-31 |
$113 |
| 2017-12-31 |
$200 |
| 2017-09-30 |
$221 |
| 2017-06-30 |
$198 |
| 2017-03-31 |
$214 |
| 2016-12-31 |
$198 |
| 2016-09-30 |
$186 |
| 2016-06-30 |
$190 |
| 2016-03-31 |
$197 |
| 2015-12-31 |
$214 |
| 2015-09-30 |
$224 |
| 2015-06-30 |
$244 |
| 2015-03-31 |
$262 |
| 2014-12-31 |
$252 |
| 2014-09-30 |
$273 |
| 2014-06-30 |
$353 |
| 2014-03-31 |
$389 |
| 2013-12-31 |
$483 |
| 2013-09-30 |
$522 |
| 2013-06-30 |
$457 |
| 2013-03-31 |
$475 |
| 2012-12-31 |
$261 |
| 2012-09-30 |
$283 |
| 2012-06-30 |
$303 |
| 2012-03-31 |
$204 |
| 2011-12-31 |
$245 |
| 2011-09-30 |
$269 |
| 2011-06-30 |
$289 |
| 2011-03-31 |
$300 |
| 2010-12-31 |
$316 |
| 2010-09-30 |
$197 |
| 2010-06-30 |
$216 |
| 2010-03-31 |
$232 |
| 2009-12-31 |
$162 |
| 2009-09-30 |
$163 |
| 2009-06-30 |
$184 |
| 2009-03-31 |
$190 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.222B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
